| Literature DB >> 17722544 |
Zhi Ping Xu1, Tara L Walker, Kerh-lin Liu, Helen M Cooper, G Q Max Lu, Perry F Bartlett.
Abstract
We prepared stable homogeneous suspensions with layered double hydroxide (LDH) nanoparticles for in vitro gene delivery tests. The viability of HEK 293T cells in the presence of LDH nanoparticles at different concentrations was investigated. This revealed 50% cell viability at 500 microg/mL of LDH nanoparticles that is much higher than 50-100 microg/mL used for the delivery tests. The supercoiled pEF-eGFP plasmid (ca. 6100 base pairs) was mixed with LDH nanoparticle suspensions for anion exchange at a weight ratio of DNA/LDH between 1:25 and 1:100. In vitro experiments show that GFP expression in HEK 293T cells starts in the first day, reaches the maximum levels by the second day and continues in the third day. The GFP expression generally increases with the increase in DNA loading in DNA-LDH nanohybrids. However, the delivery efficiency with LDH nanoparticles as the agent is low. For example, the relative efficiency is 7%-15% of that of the commercial agent FuGENE 6. Three to 6% of total cells expressed GFP in an amount detectable by the FACS cytometry 2 days after transfection at 1 microg/mL of plasmid DNA with 25 microg/mL of LDH nanomaterial. The lower delivery efficiency could be attributed to the aggregation of LDH nanoparticles caused by the long-chain plasmid DNA.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17722544 PMCID: PMC2673978
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1XRD pattern of pristine Mg2Al-Cl-LDH nanomaterials.
Note: *brucite; #gibbsite.
Figure 2FTIR spectrum of pristine Mg2Al-Cl-LDH nanomaterials. Shoulder with # is characteristic of Mg2Al-Cl-LDH.
Figure 3(A) Particle size distribution and (B) Zeta potential distribution of pristine Mg2Al-Cl-LDH nanoparticle suspension.
Figure 4TEM image of typical Mg2Al-Cl-LDH.
Figure 5(A) STEM image and (B) EDX spectrum of DNA-LDH nanohybrids.
Figure 6HEK 293 cell viability versus Mg2Al-Cl-LDH concentration.
Figure 7Fluorescence microscopic images of cells with GFP expressed two days after transfection. (A) and (C): using LDH nanoparticles; (D): using the commercial agent FuGENE®6 as transfection agent ([DNA] = 1.0 μg/mL and [FuGENE®6] = 5.0 μg/mL?). (B): brightfield image of image (A).
Figure 8FACS profile of HEK 293T cells with GFP proteins transfected under various conditions. (A) Controlled experiment; (B) 1.0 μg/mL of plasmid DNA; (C) 100 μg/mL of LDHs; (D) 0.25 μg/mL of DNA and 25 μg/mL of LDH; (E) 0.50 μg/mL of DNA and 25 μg/mL of LDH; (F) 1.0 μg/mL of DNA and 25 μg/mL of LDH.
The percentage of GFP-expressing cells (above the gate at fluorescence intensity of 2000 in Figures 8 and 9).
| 1 | 0.10 ± 0.05 | 0.41 ± 0.10 | 0.40 ± 0.30 | 0.77 ± 0.39 | 1.13 ± 0.58 |
| 2 | 0.04 ± 0.02 | 0.49 ± 0.19 | 0.84 ± 0.42 | 3.23 ± 1.66 | 3.95 ± 1.48 |
| 3 | 0.04 ± 0.01 | 1.35 ± 0.50 | 0.97 ± 0.21 | 2.18 ± 1.41 | 3.27 ± 1.45 |
Note: aThe plasmid DNA concentration was 1.0 μg/mL in the tests;
bThe LDH concentration was 100 μg/mL in the tests;
cThe plasmid DNA concentration was varied at 0.25, 0.50 and 1.0 μg/mL while the LDH concentration was kept at 25 μg/mL in the tests;
dThe average percentage and standard deviation were calculated from the data in 3 or 4 experiments.